White Paper: Advancing Clinical Oncology Research With ddPCR™ Technology
The demand for personalized cancer therapies has never been greater. To match patients with the most effective treatments and monitor how disease responds over time, clinicians are increasingly relying on molecular biomarkers to guide care decisions. This approach requires highly accurate, quantitative molecular technologies capable of detecting and tracking genomic biomarkers across every stage of disease. Droplet Digital™ PCR (ddPCR) technology partitions each sample into tens of thousands of individual droplets to deliver the absolute quantification and low-frequency variant detection needed to support these evolving applications in research settings.
Download this white paper to learn:
- How clinical oncology is transforming cancer research
- Why molecular biomarkers are essential for personalized patient management
- The opportunities and challenges of liquid biopsy, MRD monitoring, and multi-cancer early detection
- How ddPCR technology complements NGS to deliver highly sensitive, quantitative biomarker analysis
- Key applications of ddPCR technology for mutation profiling, DNA methylation studies, and longitudinal molecular analysis in research settings
Featured Content
Download the White Paper
Share a little information with us to download the entire white paper now.